Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
Mesleh Shayeb A, Urman D, Dizman N, Meza L, Sivakumar A, Gan C, Dzimitrowicz H, Zhang T, Barata P, Bilen M, Gao X, Heng D, Pal S, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 291-291. DOI: 10.1200/jco.2021.39.6_suppl.291.Peer-Reviewed Original ResearchLow molecular weight heparinDirect oral anticoagulantsRenal cell carcinomaAdvanced renal cell carcinomaMajor bleeding eventsVenous thromboembolismBleeding eventsMajor bleedingSafety profileDifferent anticoagulantsSimilar bleeding riskRecurrent venous thromboembolismClear cell histologyRetrospective multicenter studyMolecular weight heparinCause of deathFisher's exact testLMWH useRCC outcomeBleeding riskMedian doseOral anticoagulantsPrimary endpointSecondary endpointsVTE events